Elanco(US:ELAN) Prnewswire·2025-09-08 10:27Core Insights - Elanco Animal Health has made significant advancements with its latest pet health innovations, Credelio Quattro and Zenrelia, showcasing its commitment to enhancing treatment standards for pets and veterinarians globally [1] Group 1: Credelio Quattro - Credelio Quattro has become Elanco's fastest pet health blockbuster, achieving $100 million in net sales in under eight months, marking it as one of the industry's fastest products to reach this milestone [2][5] - The product provides comprehensive parasite protection against six types of parasites, including fleas, ticks, heartworm disease, and three intestinal parasites [2] - In June, Credelio Quattro captured approximately 14% of the dollar share in broad-spectrum sales from U.S. veterinary clinics, indicating strong demand for all-in-one products [2] - Elanco plans to expand Credelio Quattro globally, with submissions for approval in multiple countries, including Australia, Canada, the EU, the UK, and Japan, expected to begin in 2026 [3] Group 2: Zenrelia - Zenrelia is a once-daily oral JAK inhibitor that has gained approval in the UK and is now available in the EU and Great Britain, aimed at improving the quality of life for pets and their owners [4][6] - The product is designed to control itching and inflammation associated with skin allergies in dogs over 12 months of age [10] - Elanco has conducted a head-to-head non-inferiority study comparing Zenrelia to the incumbent product Apoquel, demonstrating its effectiveness in treating atopic dermatitis [7]